Targeting the Gut–Heart Axis in Diabetic Heart Failure: Microbiota and SGLT2is as Converging Therapeutic Frontiers
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27094101 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Yen Chu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Thoracic and Cardiovascular Surgery, Chang Gung Memorial Hospital Linkou Branch, Taoyuan 33305, Taiwan. Hauptthemen laut MEDLINE: Heart Failure, Sodium-Glucose Transporter 2 Inhibitors, Gastrointestinal Microbiome, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Linkou Chang Gung Memorial Hospital, Chang Gung Memorial Hospital, Linkou Branch, National Science and Technology Council.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Emerging evidence highlights the gut microbiota as a critical modulator in the pathogenesis of heart failure (HF), particularly among patients with type 2 diabetes mellitus (T2DM). Dysbiosis contributes to systemic inflammation, endothelial dysfunction, and adverse cardiac remodeling via microbial metabolites such as trimethylamine N-oxide (TMAO) and short-chain fatty acids (SCFAs). However, the therapeutic intersection between the gut microbiota and pharmacological interventions remains insufficiently integrated. Sodium-glucose cotransporter-2 inhibitors (SGLT2is), a cornerstone of T2DM management, confer cardioprotective effects that may involve microbiota-mediated pathways. This review provides a novel synthesis of how SGLT2is influence gut ecology, specifically through altered glucose excretion and osmotic shifts, to potentially restore SCFA-producing taxa. By delineating the structural transitions from gut physiology to SGLT2i-modulated cardiac outcomes, we emphasize the gut–heart axis as a pivotal therapeutic target. This focused framework offers new insights into the triadic interplay between microbiome stability and cardiometabolic health, moving beyond traditional glucose-centric paradigms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Thoracic and Cardiovascular Surgery, Chang Gung Memorial Hospital Linkou Branch, Taoyuan 33305, Taiwan.
- Laboratory of Cardiovascular Physiology, Chang Gung Memorial Hospital Linkou Branch, Taoyuan 33305, Taiwan.
- Department of Research and Development, Chang Gung Memorial Hospital Linkou Branch, No. 5, Fuxing St., Guishan Dist., Taoyuan 33305, Taiwan.
- Department of Nursing, College of Nursing, Chang Gung University of Science and Technology, No. 261, Wenhua 1st Rd., Guishan Dist., Taoyuan 33303, Taiwan.
- Graduate Institute of Traditional Chinese Medicine, The Medical College, Chang Gung University, No. 259, Wenhua 1st Rd., Guishan Dist., Taoyuan 33302, Taiwan.
- Department of Laboratory Medicine, Section of Clinical Serology and Immunology, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan 33305, Taiwan.
ORCID-Profile: Yen Chu, Chi-Nan Tseng
Förderung
- Linkou Chang Gung Memorial Hospital
- Chang Gung Memorial Hospital, Linkou Branch
- National Science and Technology Council
Zitieren
APA
Chu, Y., Huang, K. H., & Tseng, C. N. (2026). Targeting the Gut–Heart Axis in Diabetic Heart Failure: Microbiota and SGLT2is as Converging Therapeutic Frontiers. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27094101
Vancouver
Chu Y, Huang KH, Tseng CN. Targeting the Gut–Heart Axis in Diabetic Heart Failure: Microbiota and SGLT2is as Converging Therapeutic Frontiers. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27094101
BibTeX
@article{Chu2026,
author = {Chu, Yen and Huang, Kuo-Hsiung and Tseng, Chi-Nan},
title = {Targeting the Gut–Heart Axis in Diabetic Heart Failure: Microbiota and SGLT2is as Converging Therapeutic Frontiers},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27094101}
}
EUVIMED